These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 18718095

  • 1. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
    Gu WJ, Xu W, Qian SX, Wu YJ, Hong M, Chen LJ, Wu HX, Lu H, Qiu HX, Li JY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
    Li F, Yi SH, Yu Z, Xing LJ, Xu Y, Qi JY, Zhao YZ, Li ZJ, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
    [Abstract] [Full Text] [Related]

  • 5. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
    Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M.
    J Clin Oncol; 2005 Jun 20; 23(18):4070-8. PubMed ID: 15767647
    [Abstract] [Full Text] [Related]

  • 6. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T, Lech-Maranda E, Robak P.
    Expert Rev Anticancer Ther; 2010 Oct 20; 10(10):1529-43. PubMed ID: 20942624
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
    Nunes AA, da Silva AS, Souza KM, Koury Cde N, de Mello LM.
    Crit Rev Oncol Hematol; 2015 Jun 20; 94(3):261-9. PubMed ID: 25797826
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S.
    Blood; 2010 Jan 21; 115(3):489-95. PubMed ID: 19843887
    [Abstract] [Full Text] [Related]

  • 14. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
    Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group.
    Lancet; 2010 Oct 02; 376(9747):1164-74. PubMed ID: 20888994
    [Abstract] [Full Text] [Related]

  • 15. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
    Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ.
    Leuk Res; 2010 Mar 02; 34(3):284-8. PubMed ID: 19646755
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
    Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde DW, Scheinberg DA, Zelenetz AD, Weiss MA.
    J Clin Oncol; 2009 Feb 01; 27(4):491-7. PubMed ID: 19075280
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM.
    Cancer; 2015 Nov 01; 121(21):3869-76. PubMed ID: 26218678
    [Abstract] [Full Text] [Related]

  • 20. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI.
    J Clin Oncol; 2010 Apr 01; 28(10):1756-65. PubMed ID: 20194844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.